The National Institute for Health and Care Excellence announced final draft guidance recommending the PARP inhibitor olaparib for patients with HER2-negative, high-risk early breast cancer harboring a BRCA1/2 mutation, as well as for those with previously treated hormone-relapsed metastatic prostate cancer with a BRCA1/2 mutation.

Related Keywords

Helen Knight , Olympia Clinical Trial Steering Committee , National Institute For Health , Astrazeneca , National Health Service , National Institute , Care Excellence , National Institute For Health And Care Excellence , Nice Guidance , Olaparib Lynparza , Her2 Negative , High Risk Early Breast Cancer , Rca1 2 Mutation , Hormone Relapsed Metastatic Prostate Cancer , Profound Trial , Olympia Trial ,